secwatch.observer — SEC 8-K summary
======================================

Issuer:     EAGLE PHARMACEUTICALS, INC. (—)
CIK:        0000827871
Form:       8-K
Filed at:   2024-03-01T23:59:59+00:00
Accession:  0001104659-24-029624
Event type: debt
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eagle Pharma extends credit-agreement financial-statement deadline to May 13; restrictions stay
--------------------------------------------------------------------------------

- Second Amendment extends delivery of FY2023 audited and restated Q2/Q3 2023 financials to May 13, 2024.
- Temporary restrictions (reduced availability to $50M, no negative covenant flexibility) continue until both annual and quarterly financials delivered.
- Failure to meet deadline would result in an event of default, allowing lenders to accelerate ~$100M debt and foreclose on assets.
- Company had previously waived minimum-liquidity covenant; remains in ongoing default waiver period under credit agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/827871/000110465924029624/0001104659-24-029624-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/827871/000110465924029624/tm247692d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-029624

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer